Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | BMP4 | P12644 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473570 | 0.84 | CYP17A1 (0.46) | CDK2KDRBMP4CCNA2ALDH1A3 | |
| SCHEMBL12970192 | 0.84 | CCNE1 (0.47) | CDK2CCNE1BMP4IRAK4RPS6KA3 | |
| SCHEMBL2591159 | 0.82 | CYP17A1 (0.51) | KDRBMP4ADRA2AADRA1DADRA1A | |
| SCHEMBL5354714 | 0.80 | ALOX15 (0.53) | KDRBMP4MEN1NPC1RAB9A | |
| SCHEMBL19305220 | 0.79 | ADORA2A (0.44) | KDRBMP4MEN1NPC1RAB9A | |
| SCHEMBL3357416 | 0.79 | BMP4 (0.39) | CDK2KDRBMP4IRAK4JAK1 | |
| SCHEMBL7112314 | 0.78 | KDR (0.59) | CDK2KDRBMP4IRAK4MEN1 | |
| SCHEMBL15473727 | 0.76 | KDR (0.54) | KDRALDH1A3MEN1RAB9AKMT2A | |
| SCHEMBL530189 | 0.74 | CDK2 (0.40) | CDK2CCNE1KDRIRAK4ADRA2A | |
| SCHEMBL4672079 | 0.73 | ALDH1A3 (0.54) | CDK2CCNE1KDRIRAK4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180212-B2 | β-amyloid plaque imaging agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2694510-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20130315826-A1 | Beta-Amyloid Plaque Imaging Agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012136776-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| US-7737183-B2 | β-amyloid and neurofibrillary tangle imaging agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
| US-20090004107-A1 | BETA-AMYLOID AND NEUROFIBRILLARY TANGLE IMAGING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315826-A1 | Beta-Amyloid Plaque Imaging Agents | APP, SLC6A2, BACE1 | CDK2 4659/4885CCNE1 4417/4885KDR 1743/4885 |
| US-20090004107-A1 | BETA-AMYLOID AND NEUROFIBRILLARY TANGLE IMAGING AGENTS | APP, PSEN1, PSEN2 | CDK2 3372/4885CCNE1 2340/4885KDR 1211/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | CDK2 54/4885CCNE1 290/4885KDR 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.